Table 4.

Comparison to RAMs combinations decreasing response to dolutegravir in the VIKING-3 study

RAMs combinations after RAL use	Prevalence (%)
	VIKING-3 [15]	This study
No INSTIs mutations	33	48
No Q148a	36	40
Q148 + 1 secondary mutationb	20	8
Q148 + ≥2 secondary mutationsb	11	4

RAMs resistance associated mutations, RAL raltegravir, INSTIs integrase strand transfer inhibitors

^aY143, N155, T66 or E92

^bG140A/C/S, L74I or E138A/K/T